Lyell Immunopharma (NASDAQ:LYEL) Shares Up 5.5% – Here’s Why

by · The Markets Daily

Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Free Report)’s share price was up 5.5% during mid-day trading on Tuesday . The stock traded as high as $39.68 and last traded at $39.4370. Approximately 69,733 shares were traded during trading, a decline of 3% from the average daily volume of 71,991 shares. The stock had previously closed at $37.37.

Analyst Ratings Changes

LYEL has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Wednesday, October 8th. HC Wainwright upgraded shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and raised their price target for the stock from $20.00 to $45.00 in a research note on Tuesday, December 9th. Finally, Wall Street Zen upgraded Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Monday, September 1st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $45.00.

Check Out Our Latest Stock Analysis on Lyell Immunopharma

Lyell Immunopharma Price Performance

The firm’s 50 day moving average is $21.82 and its 200 day moving average is $15.25. The company has a market cap of $800.90 million, a PE ratio of -1.64 and a beta of -0.11.

Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.81) by $0.68. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%.The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.01 million. As a group, analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Nuveen LLC bought a new stake in shares of Lyell Immunopharma during the 1st quarter worth $345,000. Almitas Capital LLC grew its position in Lyell Immunopharma by 136.3% during the first quarter. Almitas Capital LLC now owns 2,482,606 shares of the company’s stock valued at $1,336,000 after acquiring an additional 1,432,086 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after acquiring an additional 154,327 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Lyell Immunopharma by 204.2% in the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock worth $354,000 after acquiring an additional 443,614 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of Lyell Immunopharma in the 2nd quarter worth approximately $258,000. 66.05% of the stock is currently owned by institutional investors.

Lyell Immunopharma Company Profile

(Get Free Report)

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.

See Also